|
Post by parrerob on Jan 9, 2016 15:51:16 GMT -5
still waiting some good news within q1 from TS ? May be a new product coming up ?
Do You all believe, at this point, that the declaration from Hakan is to consider waste ?
Just curious .....
|
|
|
Post by BlueCat on Jan 9, 2016 16:03:58 GMT -5
He did say Q4. Q1 would be close enough.
But if that was truly vaporware, that would fuel the lawsuit material and explain the departure after as CEO.
|
|
|
Post by dictatorsaurus on Jan 9, 2016 16:04:00 GMT -5
I actually think if Mannkind is to be saved it will be through TS, not Afrezza.
Afrezza has a long way to go before it gets recognition and becomes profitable.
|
|
|
Post by jimo on Jan 9, 2016 17:03:59 GMT -5
Hakan got fired for making statements that are going to show up in the flood of lawsuits coming now. He was desperate and said some very misleading things on the last two CCs. I believe if Afrezza makes it then TS will make and the other way around.
|
|
|
Post by seanismorris on Jan 9, 2016 17:43:41 GMT -5
I thought Hakan was fired because he didn't have a plan. A CEO without a plan gets canned.
I'm convinced he was planning to sit on his hands until MannKind went bankrupt.
I doubt there will be any significant lawsuits. MannKinds management has been careful to not say anything meaningful, which has been investors problem.
Why Al ever made Hakan the CEO is anyone's guess...
Saying they think there will be a TS partnership in Q1 isn't grounds for a lawsuit. See: disclaimer before every CC.
|
|
|
Post by parrerob on Jan 9, 2016 17:49:50 GMT -5
Hakan fired for that reason is very strange.... The press release does not match with Your story about lawsuites, IMO. He is still in the company and officially working for the transition. He got a wonderful package ($$$) and this too does not match with the lawsuites too.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 9, 2016 17:54:05 GMT -5
Everyone knows if Afrezza is given back to Mannkind, Hakan is not the right CEO as he doesnt have that credentials... So it was good for all for him to step down
|
|
|
Post by mnholdem on Jan 9, 2016 19:02:20 GMT -5
First, Hakan did not promise anything except that he would provide news on a partnership. That's promising nothing but an update. Second, Hakan was not fired. He resigned and then was asked by the BoD to remain on board to assist with the transition. Third, every conference begins with a disclaimer that protects the company from liability if any forward-looking statements to not come to fruition.
I doubt any lawsuit against MannKind could succeed.
|
|
|
Post by mnkdnewb on Jan 9, 2016 22:22:59 GMT -5
First, Hakan did not promise anything except that he would provide news on a partnership. That's promising nothing but an update. Second, Hakan was not fired. He resigned and then was asked by the BoD to remain on board to assist with the transition. Third, every conference begins with a disclaimer that protects the company from liability if any forward-looking statements to not come to fruition. I doubt any lawsuit against MannKind could succeed. What are your (and others) thoughts on what "transition" they are referring to now that we know the sny partnership is over?
|
|
|
Post by suebeeee1 on Jan 10, 2016 0:11:18 GMT -5
still waiting some good news within q1 from TS ? May be a new product coming up ? Do You all believe, at this point, that the declaration from Hakan is to consider waste ? Just curious ..... Maybe I'm naive or just know how good the product is, but I still believe that MNKD can not only survive, but thrive. Will it be easy? Hell no! But in some ways, that will make this story even better. I am waiting expectantly for next week's conference. Only if MNKDs management continues their ungodly silence will I believe they are on death's row. I expect good news.
|
|
|
Post by mnholdem on Jan 10, 2016 10:04:00 GMT -5
I suppose by "transition" the PR was referring to Hakan helping the new CEO, especially in understand all things related to Technosphere chemistry and manufacturing, which were Edstrom's forte.
|
|
|
Post by themarlin on Jan 10, 2016 10:49:48 GMT -5
I actually think if Mannkind is to be saved it will be through TS, not Afrezza. Afrezza has a long way to go before it gets recognition and becomes profitable. Doesn't TS also have a long way to go, as in a new TS application and trials will also take a long time?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 10, 2016 10:59:57 GMT -5
I actually think if Mannkind is to be saved it will be through TS, not Afrezza. Afrezza has a long way to go before it gets recognition and becomes profitable. Doesn't TS also have a long way to go, as in a new TS application and trials will also take a long time? I hope you understand that a TS deal will bring much needed up front licensing $$$ that can be used for commercializing Afrezza
|
|
|
Post by vestful on Jan 10, 2016 11:14:41 GMT -5
Suebeeee1 "Maybe I'm naive or just know how good the product is, but I still believe that MNKD can not only survive, but thrive. Will it be easy? Hell no! But in some ways, that will make this story even better.
I am waiting expectantly for next week's conference. Only if MNKDs management continues their ungodly silence will I believe they are on death's row. I expect good news."
I like your enthusiasm and also expect to hear something about TS(all beit probably small). Hopefully we don't have technical malfunctions and time constraints like the last conference. That was painful.
|
|
|
Post by mnholdem on Jan 10, 2016 12:42:30 GMT -5
I actually think if Mannkind is to be saved it will be through TS, not Afrezza. Afrezza has a long way to go before it gets recognition and becomes profitable. Doesn't TS also have a long way to go, as in a new TS application and trials will also take a long time? Management did provide shareholders with a general answer to this question at the 2Q earnings call. Technosphere is now an FDA-approved drug delivery technology and, therefore, if it is used to deliver an FDA-approved active pharmaceutical ingredient (API) much of the safety testing on the drug & device has already been done. MannKind has stated that they are first developing FDA-approved API for the express purpose of expediting the FDA approval process and getting the newly-developed API(TS) to market ASAP.
|
|